Skip to content
← Holders

Davern Capital Partners, LP

What Davern Capital Partners, LP reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 2003147 · Filed Nov 12, 2026

Positions
17
Reported value
$514.1M
Opened
5
Closed
3
Other managers included
0

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Dec 31, 2025$309.3M
    14 positions
  2. Mar 31, 2026$364.5M
    17 positions
  3. Jun 30, 2026$586.5M
    15 positions
  4. Sep 30, 2026$514.1M
    17 positions
SecuritySharesChangeValueOf portfolio
BNTXBioNTech SE
682.1K−9.6%$67.1M13%
RPRXRoyalty Pharma plc
974.4K−15.7%$56.9M11.1%
INSMInsmed Inc
496K−11.4%$56.6M11%
ROIVRoivant Sciences Ltd.
1.5M−23.8%$53.9M10.5%
IONSIonis Pharmaceuticals Inc
1.1M+36.1%$48.5M9.4%
ARGXArgenx SE
37.6KNew$36.1M7%
REGNRegeneron Pharmaceuticals, Inc.
40.7K−56.1%$30.8M6%
NTRANatera, Inc.
63.2K−46.9%$26.1M5.1%
ABVXAbivax S.A.
219.2KNew$21.7M4.2%
VERAVera Therapeutics, Inc.
628.3K+25.9%$20.3M3.9%
MLYSMineralys Therapeutics, Inc.
695.2K−19.1%$17.5M3.4%
LEGNLegend Biotech Corp
828.9K−30.4%$16.5M3.2%
ARWRArrowhead Pharmaceuticals, Inc.
229.3KNew$15M2.9%
LLYEli Lilly & Co
12.6KNew$14.6M2.8%
GENBGenerate Biomedicines, Inc.
824.7K±0%$12.4M2.4%
VRDNViridian Therapeutics, Inc.
560.7KNew$11.5M2.2%
AVTXAvalo Therapeutics, Inc.
564.4K+20.4%$8.7M1.7%